Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.

METHODS: In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume.

RESULTS: Overall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P = 0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P = 0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P = 0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups.

CONCLUSIONS: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind383
Udgave nummer6
Sider (fra-til)546-557
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 6 aug. 2020

Bibliografisk note

Copyright © 2020 Massachusetts Medical Society.

ID: 61640471